We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-8.99%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$798M
AUM Growth
-$110M
Cap. Flow
-$2.61M
Cap. Flow %
-0.33%
Top 10 Hldgs %
29.72%
Holding
97
New
9
Increased
24
Reduced
42
Closed
4

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
2
MRK icon
Merck
MRK
+$18.1M
3
ABBV icon
AbbVie
ABBV
+$11.7M
4
NKTR icon
Nektar Therapeutics
NKTR
+$11.6M
5
ESPR
Esperion Therapeutics
ESPR
+$9.66M

Top Sells

Rank Stock Value
1
HBNC icon
Horizon Bancorp
HBNC
+$26.2M
2
HUM icon
Humana
HUM
+$12.6M
3
INCY icon
Incyte
INCY
+$8.5M
4
ELV icon
Elevance Health
ELV
+$8.22M
5
HCA icon
HCA Healthcare
HCA
+$7.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.7%
2 Industrials 0.42%
3 Technology 0.13%
4 Financials 0.1%
5 Energy 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GTHX
26
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$12.2M 1.53%
535,657
+261,383
+95% +$8.24M
CI icon
27
Cigna
CI
$74.6B
$12.1M 1.52%
80,000
-16,191
-17% -$2.64M
IMMU
28
DELISTED
Immunomedics Inc
IMMU
$11.3M 1.41%
850,000
-1,367
-0.2% -$20.1K
TMO icon
29
Thermo Fisher Scientific
TMO
$220B
$11.1M 1.39%
38,000
+8,200
+28% +$2.35M
KYNB
30
Kyntra Bio
KYNB
$29.4M
$10.9M 1.37%
11,800
-2,098
-15% -$2.3M
MYOK
31
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$10.4M 1.31%
200,000
-25,024
-11% -$1.33M
XNCR icon
32
Xencor
XNCR
$1.55B
$10.2M 1.28%
302,523
-17,269
-5% -$689K
MGNX icon
33
MacroGenics
MGNX
$257M
$10.2M 1.28%
799,373
-57,796
-7% -$832K
EXAS
34
DELISTED
Exact Sciences
EXAS
$9.74M 1.22%
107,786
+17,786
+20% +$2.03M
IOVA icon
35
Iovance Biotherapeutics
IOVA
$2.87B
$9.46M 1.19%
520,000
-230,700
-31% -$5.1M
AERI
36
DELISTED
Aerie Pharmaceuticals
AERI
$9.13M 1.14%
475,000
+215,000
+83% +$4.93M
HCA icon
37
HCA Healthcare
HCA
$89.5B
$9.03M 1.13%
75,000
-61,164
-45% -$7.9M
LIVN icon
38
LivaNova
LIVN
$4.2B
$8.86M 1.11%
120,000
-30,000
-20% -$2.31M
COR icon
39
Cencora
COR
$61.2B
$8.15M 1.02%
99,000
-42,520
-30% -$3.65M
EW icon
40
Edwards Lifesciences
EW
$51.7B
$8.04M 1.01%
109,755
+15,000
+16% +$1.05M
AGIO icon
41
Agios Pharmaceuticals
AGIO
$1.93B
$7.94M 1%
245,002
+45,002
+23% +$1.86M
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.79M 0.98%
100,000
-82,008
-45% -$7.7M
MDCO
43
DELISTED
Medicines Co
MDCO
$7.65M 0.96%
153,000
-47,000
-24% -$1.87M
CNC icon
44
Centene
CNC
$32.5B
$7.57M 0.95%
175,000
-120,000
-41% -$5.84M
ARNA
45
DELISTED
Arena Pharmaceuticals Inc
ARNA
$7.09M 0.89%
155,000
-15,000
-9% -$843K
SGMO
46
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.65M 0.83%
734,811
-59,146
-7% -$664K
OMCL icon
47
Omnicell
OMCL
$1.68B
$6.5M 0.82%
90,000
-10,375
-10% -$761K
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.35M 0.8%
850,000
-99,833
-11% -$957K
AMRN
49
Amarin Corp
AMRN
$303M
$6.06M 0.76%
20,000
+2,460
+14% +$859K
CHRS icon
50
Coherus Oncology
CHRS
$196M
$5.88M 0.74%
290,000
-100,000
-26% -$2M
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2019 Portfolio in Review

As of Q3 2019, Rhenman & Partners Asset Management held 97 positions worth $798M, down 12% from $908M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management's Q3 2019 filing shows 9 new, 24 increased, 42 reduced and 4 closed positions. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,025,000 shares worth $27.9M. The largest sale was Horizon Bancorp, an estimated $26.2M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Industrials and Technology.

  • Rhenman & Partners Asset Management's largest Q3 2019 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,025,000 shares worth $27.9M.
  • Rhenman & Partners Asset Management added most to Nektar Therapeutics in Q3 2019, an estimated $11.6M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2019 reduction was Humana, cutting an estimated $12.6M.
  • Rhenman & Partners Asset Management fully exited Horizon Bancorp in Q3 2019, selling an estimated $26.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $798M portfolio in Q3 2019.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 4 in Q3 2019.
  • Rhenman & Partners Asset Management's portfolio value fell 12% quarter-over-quarter to $798M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2019, filed 16 Oct 2019.